Caxton Corp as of Sept. 30, 2018
Portfolio Holdings for Caxton Corp
Caxton Corp holds 29 positions in its portfolio as reported in the September 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Strongbridge Bioph shs usd | 28.2 | $31M | 6.3M | 4.85 | |
| Mei Pharma | 14.7 | $16M | 3.7M | 4.31 | |
| Spdr S&p 500 Etf (SPY) | 13.8 | $15M | 51k | 290.72 | |
| Garrison Capital | 8.5 | $9.2M | 1.1M | 8.28 | |
| Molecular Templates | 8.0 | $8.6M | 1.6M | 5.39 | |
| Cm Fin | 7.1 | $7.7M | 895k | 8.60 | |
| Scynexis | 4.8 | $5.2M | 4.3M | 1.20 | |
| Alerian Mlp Etf | 4.1 | $4.5M | 418k | 10.68 | |
| Berkshire Hathaway (BRK.B) | 1.8 | $2.0M | 9.3k | 214.13 | |
| Jbg Smith Properties (JBGS) | 1.4 | $1.5M | 41k | 36.82 | |
| PG&E Corporation (PCG) | 1.0 | $1.0M | 23k | 46.00 | |
| Amer (UHAL) | 0.9 | $963k | 2.7k | 356.67 | |
| Tapimmune | 0.7 | $738k | 82k | 9.05 | |
| Kura Oncology (KURA) | 0.6 | $607k | 35k | 17.49 | |
| Aclaris Therapeutics (ACRS) | 0.5 | $577k | 40k | 14.51 | |
| ArQule | 0.5 | $511k | 90k | 5.66 | |
| Kala Pharmaceuticals | 0.5 | $506k | 51k | 9.87 | |
| Cti Biopharma | 0.4 | $427k | 198k | 2.16 | |
| Intec Pharma | 0.3 | $364k | 64k | 5.65 | |
| Alcentra Cap | 0.3 | $345k | 58k | 5.98 | |
| Eiger Biopharmaceuticals | 0.3 | $306k | 26k | 12.00 | |
| Catalyst Pharmaceutical Partners (CPRX) | 0.2 | $276k | 73k | 3.78 | |
| Spring Bk Pharmaceuticals In | 0.2 | $253k | 21k | 12.06 | |
| Far Pt Acquisition Corp unit 06/01/2025 | 0.2 | $237k | 23k | 10.29 | |
| Dicerna Pharmaceuticals | 0.2 | $225k | 15k | 15.28 | |
| Sunesis Pharmaceuticals Inc Ne | 0.2 | $222k | 111k | 2.00 | |
| Credit Acceptance (CACC) | 0.2 | $201k | 459.00 | 437.91 | |
| Marinus Pharmaceuticals | 0.2 | $202k | 20k | 10.01 | |
| Sierra Oncology | 0.2 | $190k | 112k | 1.70 |
